Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 12/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285071 | 1.00 | PLK1 (0.47) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6286993 | 0.95 | PLK1 (0.50) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6286987 | 0.95 | PLK1 (0.50) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6285419 | 0.85 | HTR6 (0.48) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6285413 | 0.85 | HTR6 (0.48) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6281981 | 0.84 | TNFSF11 (0.44) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6285605 | 0.84 | HTR6 (0.42) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6281979 | 0.84 | TNFSF11 (0.44) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6285611 | 0.84 | HTR6 (0.42) | PLK1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6278622 | 0.84 | HTR6 (0.44) | PLK1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | claimed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | claimed |
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | PLK1 2857/4885MEN1 3107/4885KMT2A 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.